Research programme: anti-cancer immunotherapeutics - QUE Oncology

Drug Profile

Research programme: anti-cancer immunotherapeutics - QUE Oncology

Alternative Names: Q 204

Latest Information Update: 08 Jun 2016

Price : $50

At a glance

  • Originator QUE Oncology
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malignant melanoma

Most Recent Events

  • 08 Jun 2016 Preclinical trials in Malignant melanoma in USA (unspecified route) before June 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top